AB Science SA, of Paris

AB-8939

Microtubule destabilizer

Acute myeloid leukemia

EMA validated clinical development program through a scientific advice procedure

Alexion Pharmaceuticals Inc., of Boston

Ultomiris (ravulizumab)

Long-acting C5 complement inhibitor

Paroxysmal nocturnal hemoglobinuria

European Commission approved for use in adults with hemolysis with clinical symptoms indicative of high disease activity and also for adults who are clinically stable after treatment with Soliris for at least the past 6 months

Cyxone AB, of Stockholm

Rabeximod

Immunomodulator

Rheumatoid arthritis

Submitted application to Polish regulators for permission to start phase IIb trial

Grifols SA, of Barcelona, Spain

Xembify (immune globulin subcutaneous, human- klhw)

20% subcutaneous immunoglobulin

Primary immunodeficiencies

Approved by FDA

Notes

For more information about individual companies and/or products, see Cortellis.